NCT06193577 Effect of Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters
| NCT ID | NCT06193577 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IBSA Farmaceutici Italia Srl |
| Condition | Weight Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-11-08 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-11-08 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of the efficacy of Phaseolus vulgaris L. dry extract on weight modulation.
Eligibility Criteria
Inclusion Criteria: * Male subjects aged between 18 and 60 years * BMI between 25 and 35 kg/m2 * Habitual consumption of three main meals a day * Stable body weight during the 3 months prior to enrollment * Commitment to adhere to the diet and avoid the use of other weight loss products during the study * Commitment not to change lifestyle significantly for the entire duration of the study. * Signing of informed consent Exclusion Criteria: * Hypergonadotropic hypogonadism and hypogonadotropic hypogonadism * Diabetes mellitus * Smoking \> 10 cigarettes/day * Alcohol \> 2 alcohol units/day (equal to 24 g of ethanol) * History of eating disorders during the 12 months prior to enrollment * Use of any drug or product to treat obesity (e.g. meal replacements) * Presence of acute or chronic gastrointestinal diseases * Active use of drugs that could influence the functions: gastrointestinal (e.g. laxatives, etc.), insulin (insulin sensitizers, etc.) and/or testicular (hormones, substances that influece testosterone production * Known sensitivity to the ingredients of the preparation * Any other clinical condition judged by the investigator to be incompatible with participation in the trial
Contact & Investigator
Aldo Calogero, Prof.
PRINCIPAL INVESTIGATOR
Università di Catania
Frequently Asked Questions
Who can join the NCT06193577 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 60 Years, studying Weight Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06193577 currently recruiting?
Yes, NCT06193577 is actively recruiting participants. Contact the research team at carmelo.gusmano@yahoo.it for enrollment information.
Where is the NCT06193577 trial being conducted?
This trial is being conducted at Catania, Italy.
Who is sponsoring the NCT06193577 clinical trial?
NCT06193577 is sponsored by IBSA Farmaceutici Italia Srl. The principal investigator is Aldo Calogero, Prof. at Università di Catania. The trial plans to enroll 60 participants.